![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication October 12, 2005.
Revised November 14, 2005.
Accepted for publication November 15, 2005.
Gemfibrozil more potently inhibits CYP2C9 than CYP2C8 in vitro, and yet the opposite inhibitory potency is observed in the clinic. To investigate this apparent paradox, we evaluated both gemfibrozil and its major metabolite, an acyl-glucuronide (gemfibrozil 1-O-
-glucuronide) as direct-acting and metabolism-dependent inhibitors of the major drug-metabolizing cytochrome P450 (CYP) enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) in human liver microsomes. Gemfibrozil most potently inhibited CYP2C9 (IC50 of 30 µM), whereas, gemfibrozil glucuronide most potently inhibited CYP2C8 (IC50 of 24 µM). Unexpectedly, gemfibrozil glucuronide, but not gemfibrozil, was found to be a metabolism-dependent inhibitor of CYP2C8 only. The IC50 for inhibition of CYP2C8 by gemfibrozil glucuronide decreased from 24 µM to 1.8 µM after a 30-min incubation with human liver microsomes and NADPH. Inactivation of CYP2C8 by gemfibrozil glucuronide required NADPH, and proceeded with a KI (inhibitor concentration that supports half the maximal rate of enzyme inactivation) of 20-52 µM and a kinact (maximal rate of inactivation) of 0.21 min-1. Potent inhibition of CYP2C8 was also achieved by first incubating gemfibrozil with alamethicin-activated human liver microsomes and UDP-glucuronic acid (to form gemfibrozil glucuronide) followed by a second incubation with NADPH. LC/MS/MS analysis established that human liver microsomes and recombinant CYP2C8 both convert gemfibrozil glucuronide to a hydroxylated metabolite, with oxidative metabolism occurring on the dimethylphenoxy moiety (the group furthest from the glucuronide moiety). The results described have important implications for the mechanism of the clinical interaction reported between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone.
Key words:
CYP inhibition, CYP2C, drug-drug interactions, glucuronidation, inactivation, mechanism-based inhibition
This article has been cited by other articles:
|
|
 |
|
  G. A. Schoch, J. K. Yano, S. Sansen, P. M. Dansette, C. D. Stout, and E. F. Johnson Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID J. Biol. Chem., June 20, 2008; 283(25): 17227 - 17237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Huang, J. M. Strong, L. Zhang, K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart, et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process J. Clin. Pharmacol., June 1, 2008; 48(6): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Albrecht, A. Unger, A. K. Nussler, and S. Laufer In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase Drug Metab. Dispos., May 1, 2008; 36(5): 894 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tornio, M. Niemi, P. J. Neuvonen, and J. T. Backman Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone Drug Metab. Dispos., January 1, 2008; 36(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zielinska, C. F. Lichti, S. Bratton, N. C. Mitchell, A. Gallus-Zawada, V.-H. Le, M. Finel, G. P. Miller, A. Radominska-Pandya, and J. H. Moran Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 139 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver Drug Metab. Dispos., November 1, 2007; 35(11): 2040 - 2044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, L. Wang, G. Chandrasena, L. Ma, M. Zhu, H. Zhang, C. D. Davis, and W. G. Humphreys Involvement of Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes in the in Vitro Metabolism of Muraglitazar Drug Metab. Dispos., January 1, 2007; 35(1): 139 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Akoglu, R. Yilmaz, A. Kirkpantur, M. Arici, B. Altun, and C. Turgan Combined Organ Failure with Combination Antihyperlipidemic Treatment: A Case of Hepatic Injury and Acute Renal Failure Ann. Pharmacother., January 1, 2007; 41(1): 143 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Triplitt Drug Interactions of Medications Commonly Used in Diabetes Diabetes Spectr, October 1, 2006; 19(4): 202 - 211. [Full Text] [PDF]
|
|
|
|
|
|
L M. Gutschi, J. C Malcolm, C. M Favreau, and T. C. Ooi Paradoxically Decreased HDL-Cholesterol Levels Associated with Rosiglitazone Therapy Ann. Pharmacother., September 1, 2006; 40(9): 1672 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Nascent Transcripts: Emerging concepts from the recent literature Mol. Interv., April 1, 2006; 6(2): 67 - 67. [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, D. Zhang, A. Swaminathan, Y. Xue, P. T. Cheng, S. Wu, R. Mosqueda-Garcia, C. Aurang, D. W. Everett, and W. G. Humphreys GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14C-LABELED MURAGLITAZAR IN HUMANS: METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT BILE COLLECTION Drug Metab. Dispos., March 1, 2006; 34(3): 427 - 439. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
